Lomitapide

Drug Profile

Lomitapide

Alternative Names: AEGR-733; BMS-201038; Juxtapid; Lojuxta

Latest Information Update: 19 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Aegerion Pharmaceuticals; Amryt Pharma; Novelion Therapeutics; University of Pennsylvania
  • Class Antihyperlipidaemics; Benzamides; Biphenyl compounds; Fluorenes; Piperidines; Small molecules
  • Mechanism of Action Microsomal triglyceride transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type I; Hyperlipoproteinaemia type IIa
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hyperlipoproteinaemia type IIa

Most Recent Events

  • 16 Dec 2016 Launched for Hyperlipoproteinaemia type IIa (Adjunctive treatment) in Japan (PO)
  • 05 Dec 2016 Lomitapide licensed to Amryt Pharma in Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Malta, Middle East, Netherlands, North Africa, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom
  • 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top